Novartis, Penn In Immunotherapy Pact | Chemical & Engineering News
Volume 90 Issue 33 | p. 17 | Concentrates
Issue Date: August 13, 2012

Novartis, Penn In Immunotherapy Pact

Department: Business
Keywords: pharmaceuticals, industry-academic alliances, immunotherapy

Novartis has teamed with the University of Pennsylvania to bring chimeric antigen receptor (CAR) immunotherapies for the treatment of cancer to market. Penn’s CAR technology recodes a patient’s own T cells to express proteins found on the patient’s tumor. When reintroduced into the patient’s bloodstream, those engineered T cells can bind to and kill tumor cells. Novartis gains access to CART-19, an immunotherapy that has shown promise in a pilot study of patients with advanced chronic lymphocytic leukemia. The partners will build the Center for Advanced Cellular Therapies on the Penn campus in Philadelphia, where they plan to discover, develop, and manufacture adoptive T-cell immunotherapies.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment